TR200102228T2 - (E)-7-[4-(4-florofenil)-6-isopropil-2- [metil(metilslfonil)amino]pirimidin-5-yl] (3R,5S)-3,5-dihidroksihept-6-enoikasit ve bir inhibit”r i‡eren ila‡ kombinasyonlarì. - Google Patents

(E)-7-[4-(4-florofenil)-6-isopropil-2- [metil(metilslfonil)amino]pirimidin-5-yl] (3R,5S)-3,5-dihidroksihept-6-enoikasit ve bir inhibit”r i‡eren ila‡ kombinasyonlarì.

Info

Publication number
TR200102228T2
TR200102228T2 TR2001/02228T TR200102228T TR200102228T2 TR 200102228 T2 TR200102228 T2 TR 200102228T2 TR 2001/02228 T TR2001/02228 T TR 2001/02228T TR 200102228 T TR200102228 T TR 200102228T TR 200102228 T2 TR200102228 T2 TR 200102228T2
Authority
TR
Turkey
Prior art keywords
inhibitor
dihydroxyhept
pyrimidin
fluorophenyl
isopropyl
Prior art date
Application number
TR2001/02228T
Other languages
English (en)
Turkish (tr)
Inventor
Raza Ali
Stuart Pears John
Gerard Hutchinson Howard
Schneck Dennis
Baba Takahiko
Touchi Akira
Yamaguchi Yoshitaka
Original Assignee
Astra Zeneca Aktiebolag
Shionogi & Co. Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102228(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902593.4A external-priority patent/GB9902593D0/en
Priority claimed from GBGB9921063.5A external-priority patent/GB9921063D0/en
Priority claimed from GBGB9921064.3A external-priority patent/GB9921064D0/en
Application filed by Astra Zeneca Aktiebolag, Shionogi & Co. Ltd filed Critical Astra Zeneca Aktiebolag
Publication of TR200102228T2 publication Critical patent/TR200102228T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
TR2001/02228T 1999-02-06 2000-02-01 (E)-7-[4-(4-florofenil)-6-isopropil-2- [metil(metilslfonil)amino]pirimidin-5-yl] (3R,5S)-3,5-dihidroksihept-6-enoikasit ve bir inhibit”r i‡eren ila‡ kombinasyonlarì. TR200102228T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902593.4A GB9902593D0 (en) 1999-02-06 1999-02-06 Drug combinations
GBGB9921063.5A GB9921063D0 (en) 1999-09-08 1999-09-08 Therapy
GBGB9921064.3A GB9921064D0 (en) 1999-09-08 1999-09-08 Drug combination

Publications (1)

Publication Number Publication Date
TR200102228T2 true TR200102228T2 (tr) 2002-03-21

Family

ID=27269637

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02228T TR200102228T2 (tr) 1999-02-06 2000-02-01 (E)-7-[4-(4-florofenil)-6-isopropil-2- [metil(metilslfonil)amino]pirimidin-5-yl] (3R,5S)-3,5-dihidroksihept-6-enoikasit ve bir inhibit”r i‡eren ila‡ kombinasyonlarì.

Country Status (28)

Country Link
US (3) US6982157B1 (OSRAM)
EP (1) EP1185274B1 (OSRAM)
JP (2) JP2002536331A (OSRAM)
KR (2) KR20010101790A (OSRAM)
CN (1) CN1165310C (OSRAM)
AR (1) AR029333A1 (OSRAM)
AT (1) ATE282415T1 (OSRAM)
AU (1) AU767304B2 (OSRAM)
BR (1) BR0007999A (OSRAM)
CA (1) CA2358632C (OSRAM)
CZ (1) CZ301296B6 (OSRAM)
DE (1) DE60015965T2 (OSRAM)
EE (1) EE04929B1 (OSRAM)
EG (1) EG23858A (OSRAM)
ES (1) ES2232418T3 (OSRAM)
GB (1) GB0000710D0 (OSRAM)
ID (1) ID30485A (OSRAM)
IL (1) IL144715A0 (OSRAM)
IS (1) IS2337B (OSRAM)
MX (1) MXPA01007905A (OSRAM)
MY (1) MY130606A (OSRAM)
NO (1) NO320745B1 (OSRAM)
NZ (1) NZ512982A (OSRAM)
PL (1) PL198034B1 (OSRAM)
PT (1) PT1185274E (OSRAM)
TR (1) TR200102228T2 (OSRAM)
TW (1) TWI282738B (OSRAM)
WO (1) WO2000045817A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
KR20130103818A (ko) 2003-10-10 2013-09-24 벨로시스 파마슈티컬스 에이/에스 피브레이트를 포함하는 고형 제제
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
NZ552389A (en) 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
WO2007005941A2 (en) 2005-07-05 2007-01-11 President And Fellows Of Harvard College Liver targeted conjugates
US20090093499A1 (en) 2005-12-20 2009-04-09 Lek Pharmaceuticals D.D. Pharmaceutical composition
US20080109252A1 (en) * 2006-11-08 2008-05-08 Lafountain Andrea Predicting patient compliance with medical treatment
US20120130202A1 (en) * 2010-11-24 2012-05-24 Fujitsu Limited Diagnosis and Monitoring of Musculoskeletal Pathologies
EP3807892A1 (en) * 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
MX2022001178A (es) 2019-07-31 2022-02-22 Intas Pharmaceuticals Ltd Composicion farmaceutica que comprende inhibidores de la hmg-coa reductasa y fenofibrato.
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0521417B1 (de) * 1991-07-02 1994-11-23 Joh. A. Benckiser GmbH Zusammenfaltbare Vorratsflasche
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity

Also Published As

Publication number Publication date
BR0007999A (pt) 2001-11-06
CZ301296B6 (cs) 2010-01-06
AU767304B2 (en) 2003-11-06
JP2002536331A (ja) 2002-10-29
AR029333A1 (es) 2003-06-25
KR20010101790A (ko) 2001-11-14
PL198034B1 (pl) 2008-05-30
EE200100406A (et) 2002-10-15
MY130606A (en) 2007-07-31
KR20060117381A (ko) 2006-11-16
NO20013811D0 (no) 2001-08-03
CA2358632C (en) 2008-10-28
EE04929B1 (et) 2007-12-17
JP2007277267A (ja) 2007-10-25
PL364780A1 (en) 2004-12-13
US20060040969A1 (en) 2006-02-23
EG23858A (en) 2007-11-18
PT1185274E (pt) 2005-03-31
IS2337B (is) 2008-02-15
AU2121800A (en) 2000-08-25
TWI282738B (en) 2007-06-21
DE60015965D1 (de) 2004-12-23
CA2358632A1 (en) 2000-08-10
US20090042911A1 (en) 2009-02-12
WO2000045817A1 (en) 2000-08-10
ID30485A (id) 2001-12-13
MXPA01007905A (es) 2003-06-04
CZ20012844A3 (cs) 2001-11-14
CN1165310C (zh) 2004-09-08
US6982157B1 (en) 2006-01-03
NZ512982A (en) 2003-08-29
IL144715A0 (en) 2002-06-30
CN1338936A (zh) 2002-03-06
EP1185274B1 (en) 2004-11-17
HK1041817A1 (en) 2002-07-26
ES2232418T3 (es) 2005-06-01
EP1185274A1 (en) 2002-03-13
DE60015965T2 (de) 2006-01-05
NO320745B1 (no) 2006-01-23
IS6009A (is) 2001-07-17
GB0000710D0 (en) 2000-03-08
NO20013811L (no) 2001-10-02
ATE282415T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
TR200102228T2 (tr) (E)-7-[4-(4-florofenil)-6-isopropil-2- [metil(metilslfonil)amino]pirimidin-5-yl] (3R,5S)-3,5-dihidroksihept-6-enoikasit ve bir inhibit”r i‡eren ila‡ kombinasyonlarì.
CL2007001807A1 (es) Composicion farmaceutica oral que comprende el acido (e)-7-[4-(4-fluorofenil)-6-isopropil-2-(metil-(metilsulfonil)-pirimidin-5-il]-(3r,5s)-3,5-dihodroxihept-6enoico, o una sal de ella y con una formulacion recubridora que contiene oxido ferrico; uso de la formulacion recubridora; util como inhibidor de hmg-coa reductasa.
DK1897546T3 (da) Kombinerede sammensætninger omfattende (E)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s]-3,5-dihydroxyhept-6-enoinsyre
NO20061181L (no) Krystallformer av kalsiumslatet til Bis [(E)-7-[4-(4-Fluorfenyl)-6-Isopro -6-lsopropyl-2- [Metyfonyl) Amino] Pyrimidin-5-YL] (3R, 5S) -3,5-Dihydroksyhept-6-ensyre]
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
TR200401874T2 (tr) Tert-butil(E)- (6-[2-[4-(4-Fluorofenil)-6-izopropil-2-[metil (metilsülfonil)amino]-pirimidin-5-il]vinil (4R,6S)-2, 2-Dimetil[1,3]Dioksan-4-il)asetatın üretimi için işlem.
DK1682536T3 (da) Fremgangsmåde til fremstilling af calciumsaltet af rosuvastatin (e)-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-ensyre og krystallinske mellemprodukter deraf
DE50213202D1 (de) Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
ATE355265T1 (de) Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
DE60233899D1 (de) Neue boronatester
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
HUP0104977A2 (hu) (E)-7-[4-(4-fluor-fenil)-6-izopropil-2-(metil-/metilszulfonil/-amino)-pirimidin-5-il]-(3R,5S)-3,5-dihidroxi-6-hepténkarbonsavat és egy P450 3A4 izoenzim-inhibítort, -indukálószert vagy szubsztrátumot tartalmazó gyógyszerkombináció
SI1185274T1 (en) Drug combinations comprising (e)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(methylsulfonyl)amino)pyrimidin-5-yl)(3r,5s)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
DK1185274T3 (da) Lægemiddelkombinationer omfattende (E) - 7 -[4- (4-fluorphenyl) - 6 - isopropyl-2 [methyl(methylsulfonyl)amino ]-pyrimidin-5-yl] (3R,5S) - 3,5-dihydroxyhept-6-ensyre og en inhibitor af, en inducer af eller et substrat for P450 isoenzym 3A4
UY30336A1 (es) Composiciones farmacéuticas conteniendo ácido (e)-7-(4-(4-fluorofenil)-6-isopropil-2-(metil(metilsulfonil)amino)pirimidin-5-il)-(3r,5s)-3,5-dihidroxihept-6-enoico y sales farmacéuticamente aceptables de la misma